Conflict of interest: the UVB lamp and supplies used in this investigation were provided by Lumenis Inc., Santa Clara, CA, USA. The authors have no proprietary interest in this study.
Targeted UVB phototherapy for psoriasis: a preliminary study
Article first published online: 18 OCT 2007
Clinical and Experimental Dermatology
Volume 32, Issue 6, pages 642–645, November 2007
How to Cite
Lapidoth, M., Adatto, M. and David, M. (2007), Targeted UVB phototherapy for psoriasis: a preliminary study. Clinical and Experimental Dermatology, 32: 642–645. doi: 10.1111/j.1365-2230.2007.02469.x
- Issue published online: 18 OCT 2007
- Article first published online: 18 OCT 2007
- Accepted for publication 5 September 2005
Excimer laser treatment for psoriasis has been associated with good results at a lower cumulative dose than narrowband ultraviolet (UV)B protocols. To examine the clinical performance of a new targeted UVB lamp (290–320 nm; BClear™) in the treatment of plaque-type psoriasis, 28 consecutive patients attending a dermatology service were treated twice weekly with the UVB lamp for 6–18 sessions (median 10). UV doses were based on multiples of a predetermined minimal erythema dose (MED). MEDs ranged from 150 to 350 mJ/cm2; maximal dose was 8 MED. Mean cumulative fluence until remission was 12.63 J/cm2. The Psoriasis Severity Index (PSI) was measured every 2 weeks for 16 weeks. Mean PSI improvement during treatment peaked at 73% after 6 weeks, and declined to 63% at 16 weeks. At that point, 36% of the patients had a > 75% improvement in PSI, and 21% showed complete clearance. Targeted radiation with the UVB lamp is effective for the treatment of plaque-type psoriasis, requiring as few as six sessions and achieving moderately long remission. As treatment is selectively directed toward lesioned skin, normal surrounding skin is spared unnecessary radiation exposure.